Serum Erythroferrone in End Stage Renal Disease Patients; Relation to Iron Status, Anemia and Erythropoiesis Stimulating Agents

Abstract

ur study aimed to study the effect of iron and ESA therapy on Erythroferrone level and its correlations with Iron parameters and response to therapy in End stage renal disease patients. Observational prospective study was conducted on 40 patients with end stage renal disease (ESRD) (GFR < 15ml/min/1.73 mm3) with evidence of iron deficiency anemia who attended Ain Shams university Hospitals. patients subdivided into two subgroups “subgroup 1: treatment with iron and erythropoietin, subgroup 2 : treatment with iron” . The patients mean age was 51.03±11.22 years with females/males ratio 1.5. Subgroup 1 mean age was 49.96±12.05 with female/male ratio 1.5, while subgroup 2 mean age was 54.11±8.15 with female/male ratio 1.4. While control group mean age was 50.78±11.71 years with female / male ratio 1 with no significant difference in age and sex between control and both patient groups. Our study shows statistically significant increase in mean erythroferrone level post iron/EPO treatment (520.00±255.26 & 458.89±175.17 in subgroup 1 & 2 respectively) compared to baseline level (212.31±106.33 and 172.22±90.25 in subgroup 1 & 2 respectively) in subgroup